Hungary clears CanSino, Covishield vaccines
Photo by BaLL LunLa / Shutterstock.com
Hungary's National Institute of Pharmacy and Nutrition (OGYÉI) has cleared a COVID-19 vaccine developed by China's CanSino and another, called Covishield, developed by AstraZeneca and the University of Oxford, but made under license in India, Hungary's chief medical officer said at a daily press briefing on Monday.
Cecília Müller said both the CanSino and AstraZeneca/Oxford products are vector vaccines, adding that she hoped the addition of the two to Hungary's vaccine mix would boost deliveries.
Until now, Hungary has inoculated its population with the BioNTech/Pfizer, Moderna, the European-made AstraZeneca-Oxford, Chinese Sinopharm, and Russian Sputnik V vaccines.
Müller noted that 16% of the population, or 1.59 million people, had already had their first jab of COVID-19 vaccine, but added that the third wave of the pandemic was in an "extraordinarily dynamic phase".
Lender Liquidity Increases Further
Hungary Condemns Iranian Attack on Israel
Home Rental Rates in Hungary Rise 11.7% in March
Tribe Hotel Budapest Stadium Recognized at LIV Hospitality D...
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
